Details of the Active Pharmaceutical Ingredient (API)
General Information of API (ID: D00147) | |||||
---|---|---|---|---|---|
Name |
Cobimetinib
|
||||
Synonyms |
Click to Show/Hide the Synonyms of This API
Cobimetinib; 934660-93-2; GDC-0973; Cotellic; Xl-518; GDC 0973; RG7420; RG 7420; UNII-ER29L26N1X; XL 518; Cobimetinib (GDC-0973, RG7420); ER29L26N1X; C21H21F3IN3O2; CHEMBL2146883; (S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)(3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl)methanone; [3,4-Bis(Fluoranyl)-2-[(2-Fluoranyl-4-Iodanyl-Phenyl)amino]phenyl]-[3-Oxidanyl-3-[(2s)-Piperidin-2-Yl]azetidin-1-Yl]methanone; [3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-((s)-3-hydroxy-3-piperidin-2-yl-azetidin-1-yl)-methanone; Cobimetinib Butyrate; Cobimetinib [USAN:INN]; cometinib; Cobimetinib (USAN/INN); cc-456; SCHEMBL189565; GTPL7626; QCR-87; XL518;RG7420;Cobimetinib; CHEBI:90851; DTXSID60239435; EX-A673; GDC0973; GDC0973; XL518; Cobimetinib; 3556AH; BDBM50391802; MFCD22124461; NSC768068; NSC781257; NSC800075; ZINC60325170; BCP9000716; CCG-264727; CS-0521; DB05239; NSC-768068; NSC-781257; NSC-800075; VS-0129; XL518 (GDC-0973); NCGC00346455-03; NCGC00346455-05; HY-13064; Methanone, (3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(3-hydroxy-3-((2S)-2-piperidinyl)-1-azetidinyl)-; AB0072274; RO-5514041; D10405; W-5863; J-525162; Q15708292; (3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)(3-hydroxy-3-((S)-piperidin-2-yl)cyclobutyl)methanone; [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]-[3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin; [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]-[3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin-1-yl]methanone; [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]{3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin-1-yl}methanone; [3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl]-[3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin-1-yl]methanone; {3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}{3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin-1-yl}methanone
|
||||
Clinical Status |
Approved
|
||||
Disease Indication | Melanoma | ICD-11: 2C30 | [1] | ||
PubChem CID | |||||
Formula |
C21H21F3IN3O2
|
||||
Canonical SMILES |
C1CCN[C@@H](C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O
|
||||
InChI |
1S/C21H21F3IN3O2/c22-14-6-5-13(19(18(14)24)27-16-7-4-12(25)9-15(16)23)20(29)28-10-21(30,11-28)17-3-1-2-8-26-17/h4-7,9,17,26-27,30H,1-3,8,10-11H2/t17-/m0/s1
|
||||
InChIKey |
BSMCAPRUBJMWDF-KRWDZBQOSA-N
|
||||
Click to Show/Hide the Molecular Data (Structure/Property) of This API | |||||
Structure |
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=16222096"></iframe>
|
||||
3D MOL | 2D MOL | ||||
Physicochemical Properties | Molecular Weight | 531.3 | Topological Polar Surface Area | 64.599 | |
XlogP | 3.9 | Complexity | 624 | ||
Heavy Atom Count | 30 | Rotatable Bond Count | 4 | ||
Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 7 | ||
Full List of Drug Formulations (DFMs) Containing This API | ||||||
---|---|---|---|---|---|---|
Cobimetinib Fumarate eq 20mg base tablet | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Microcrystalline Cellulose; Lactose Monohydrate; Croscarmellose Sodium; Magnesium Stearate; Polyvinyl Alcohol; Titanium Dioxide; Polyethylene Glycol 3350; Talc
|
|||||
Dosage Form | Tablet | |||||
Company | Genentech | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Polyvinyl alcohol | DIG Info | Debrisoquine 4-hydroxylase (EC50 = 354.8 uM) | [2] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [3] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [3] | |||
Polyethylene glycol 3350 | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [3] | |||
Cobimetinib 20 mg tablet | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Lactose monohydrate; Magnesium stearate; Talc; Titanium dioxide; Water; Croscarmellose sodium; Polyethylene glycol 3350; Microcrystalline cellulose; Polyethylene glycol, unspecified; Polyvinyl alcohol, unspecified
|
|||||
Dosage Form | Oral Tablet | |||||
Company | Genentech | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [3] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [3] | |||
Polyethylene glycol 3350 | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [3] | |||
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.